Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

SLFN12-PDE3A complex inducer BAY 2666605

An orally bioavailable agent that triggers the formation of a complex of the two proteins Schlafen family member 12 (SLFN12) and phosphodiesterase 3A (PDE3A), with potential antineoplastic activity. Upon oral administration, SLFN12-PDE3A complex inducer BAY2666605 triggers the formation of the SLFN12-PDE3A complex. This stabilizes SLFN12 and alters the expression of a set of genes that regulate cell survival, death, and proliferation. This suppresses cell cycle progression and induces apoptosis in cancer cells that specifically express elevated levels of both of these proteins.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Schlafen12 complex inducer BAY 2666605
SLFN12/PDE3A complex inducer BAY 2666605
Code name:BAY 2666605
BAY-2666605
BAY2666605
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search